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Selection and Characterization of a 2',3'-dideoxycytidine-Resistant 
Mutant of Feline Immunodeficiency Virus (63 pp) 
Director; Thomas W. North 
A mutant of feline immunodeficiency virus (FIV), designated DCR-2c, 
was selected in cell culture in the continuous presence of 25 ^M 
2',3'-dideoxycytidine (ddC). This mutant displayed a 5-fold 
resistance to ddC, a 3-fold resistance to 2',3'-dideoxyinosine (ddl), 
a 4-fold resistance to phosphonoformic acid (PFA), slight resistance 
to 2',3'-dideoxy-3'-thiacytidine (3TC) and wild-type susceptibility 
to 3'-azido-3'-dideoxythymidine (AZT) and 9-(2-
phosphonylmethoxyethyOadenine (PMEA) compared to the wild-type 
molecular clone of FIV, 34TF10. This mutant, designated DCR-5c, 
was plaque-purified by a modification of the procedure developed in 
this lab. This plaque-purified mutant retained the phenotype of the 
mutant population, DCR-2c. DCR-5c is similar to ddC-resistant 
human immunodeficiency virus type 1 (HIV-1) in ddl cross-
resistance. It also has an RT resistant to ddCTP, like the HIV-1 
mutant. The RT purified from DCR-5c demonstrated a 10-fold 
resistance to ddCTP compared to wild-type RT. In addition, the 
sequence of the RT-encoding region of DCR-5c was elucidated and 
compared to FIV 34TF10. A single point mutation was found in the 
ddC-resistant mutant that resulted in the amino acid substitution of 
His for Asp-3. No drug resistant mutation has previously been 
described in this area in either FIV or HIV-1. This mutation is in a 
region consistent with altered binding of template-primer 
contributing to resistance. 
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INTRODUCTION 
1 
GENERAL INTRODUCTION 
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus 
and the causative agent of acquired immunodeficiency syndrome 
(AIDS) (2,14). The virus targets cells of the immune system, 
specifically the helper T lymphocytes. Infected patients are 
susceptible to many opportunistic infections due to the weakened 
immune system. HIV-1 is currently the number two killer of people 
between the ages of 25 and 45 years. Over 13 million people are 
infected with the virus today and predictions for the future are 
frightening (33). Current research into control of the disease falls 
into two categories: protective vaccines and chemotherapy. Vaccine 
development has been slowed because of the antigenic diversity of 
HIV-1. Research into chemotherapy for AIDS has achieved some 
moderate success. Four nucleoside analog inhibitors have been 
approved by the Federal Drug Administration (FDA). However, 
resistance to these FDA-approved drugs has arisen in clinical 
treatment of AIDS patients. In addition, virus resistant to 
experimental drugs have been selected in vitro. It is not known 
whether or not drug-resistant variants are pathogenic, and this 
question will significantly impact the course of therapy. In addition 
to these molecular problems which have arisen with respect to the 
virus, testing of new drugs and vaccines has presented ethical 
problems with respect to human use. Although many activists 
encourage experimental drug treatment in humans, the science 
community has sought alternatives, such as in vitro systems and 
animal models. 
Due to the many obstacles stated above, an animal model is 
essential. Not only is an animal model safer to work with for the 
scientist, but in vivo pathogenesis studies can be performed. Many 
animal models have been evaluated for use in studying HIV-1, 
including Simian immunodeficiency virus (SIV), avian retroviruses, 
murine retroviruses, severe combined-deficiency (SCID) mouse 
models, Antiviruses in sheep, goats, horses and cows, HIV type 2 
(HIV-2) infection in macaques, and feline immunodeficiency virus 
(FIV). Criteria that an animal model should meet include: 1) 
naturally occurring disease, 2) relatively inexpensive, 3) non-
infective to humans, and 4) easily manipulated in in vitro and in vivo 
studies (17). FIV has become recognized as a valuable animal model 
for AIDS for several reasons; FIV causes a natural infection in cats 
and a similar disease to human AIDS. The virus is not infectious to 
humans, and cats are much more practical and economical to work 
with than non-human primates. (17). FIV also offers both in vitro 
and in vivo systems in which to study drug resistance. 
FELINE IMMUNODEFICIENCY VIRUS 
Feline immunodeficiency virus (FIV), a lentivirus, is the 
etiological agent of a natural acquired immunodeficiency syndrome 
(AIDS) in cats (36,37). This disease occurs in domestic cats, and 
has also been produced by experimental infection of specific-
pathogen-free cats (52,58). The virus is highly T lymphotrophic 
which results in an immunodeficient state in the animal. Infected 
cats are susceptible to many opportunistic diseases, as are humans 
infected with HIV-1. FIV was first described in 1987 following 
isolation from infected cats in a cattery. At first, many believed 
the disease was caused by feline leukemia virus (FeLV), however, all 
the animals in the cattery were seronegative for FeLV, therefore 
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ruling out FeLV as the cause of this immunosuppressive disease (37). 
Since the original identification of the disease, FIV has been shown 
to be a worldwide infection of domestic cats. FIV is 
morphologically, as well as pathologically, similar to HIV-1. 
Transmission of FIV to humans, however, has not been reported. 
With these similarities in mind, FIV offers a unique opportunity to 
study as an animal model for AIDS. 
Life Cycle. FIV and HIV-1 share the prototypical life cycle of a 
retrovirus (figure 1 ). The virus is first adsorbed by a receptor on 
the host cell membrane. HIV-1 binds to the CD4 receptor on T cells. 
A CD4 homologue, CD9 has been implicated in FIV binding and 
infection (57). Once in the cell, the virus sheds its envelope and 
releases its RNA genome along with other proteins, including the 
enzyme reverse transcriptase (RT). This enzyme is unique to 
retroviruses. RT is the virally encoded RNA-dependent DNA 
polymerase responsible for synthesis of a DNA copy of the viral RNA 
genome. After synthesis of the complementary strand of DNA, the 
enzyme has a second function, that of RNase H activity. The original 
RNA strand is removed by this RNase H and a second strand of DNA is 
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Figure 1. Retrovirus life cycle from virus entry to release (drawn by 
David Hill). 
synthesized by RT. Once the double-stranded DNA has been produced, 
it is integrated by the viral protein integrase into the host genome 
as a pro virus (51). The provirus will remain dormant until some, as 
of yet unknown, factor(s) stimulates the provirus into active 
replication to produce infectious virus particles. The cell will then 
produce viral RNA and proteins. These progeny viruses assemble and 
are released from the cell surface by budding. The virus can then 
infect other cells. 
Genome structure and organization. FIV and HIV-1, are 
enveloped, single-stranded RNA viruses. The FIV virion contains two 
copies of its RNA genome which are held together by a dimer linkage 
structure (DLS) near the 5' ends. The FIV genome consists of three 
large open reading frames (orfs) corresponding to the main 
structural genes, gag, pol and env (fig 2). The three structural 
genes are flanked by long terminal repeat (LTR) regions. There exists 
an overlapping gag and pol coding sequence which is characteristic 
of Antiviruses. In addition, the FIV genome also contains several 
small orfs that are multiply spliced to generate genes that regulate 
the expression of viral proteins (22,38,39,52). Coding regions of the 
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Figure 2. Organization of the FIV genome. 
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FIV genome have been identified that are responsible for 
determining whether or not a viral infection is productive or latent 
(22,38). These regions which encode the Rev protein and the Rev-
responsive element, are also found in HIV-1. Another small orf 
contains a putative wT gene, that regulates viral infectivity and is 
similar structurally and functionally to the vif gene of HIV-1 (52). 
A putative tat orf has been described, (35,38,50) and may encode 
the FIV equivalent to the transactivating protein of virus which 
infect primates. No FIV counterpart to the HIV-1 nef gene has been 
reported. 
The entire FIV genome is approximately 9500 bases. The gag 
gene is reportedly 450 residues long and the calculated molecular 
mass of the resulting polypeptide is 24 kDa. This agrees with 
estimated mass of the core protein (p24) of FIV. The gag gene also 
encodes for two small proteins (pi 0 and pi 7)(50). The pol gene 
encodes the enzymes reverse transcriptase, integrase, a protease, 
and a protease-like protein (49) with dUTPase function (12) . The 
env gene of FIV, as with HIV-1, is located near the 3' end of the 
genome. At least four small orfs exist. Two can be found in 
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between the pol-env genes, and at least two are located in the env-
3' long terminal repeat (LTR) regions. The env gene is 
approximately 750 base pairs long. Two env gene products of FIV 
are synthesized from a 145 kDa precursor glycoprotein. The 
precursor is quickly "trimmed" to a 130 kDa glycoprotein and is 
further processed to two glycoproteins, gp95 and gp40. 
Transmission and Pathogenesis. Unlike HIV-1, sexual 
transmission does not appear to be a major factor in the spread of 
FIV. Transmission of FIV is generally through an infected cat biting 
or scratching an uninfected cat. Experimentally-infected female 
cats have been shown to transmit the virus to their offspring (56), 
although naturally-infected cats transmitting virus to offspring has 
not been reported. Vertical transmission is a significant mode of 
transmission in HIV-1. 
FIV infection causes an AIDS-like disease in cats that can be 
broken down into five distinct stages. These stages correlate to the 
levels of infection seen with HIV-1. The five clinical stages are 
acute infection, asymptomatic carrier, persistent generalized 
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lymphadenopathy, AIDS related complex (ARC) and AIDS (21). With 
FIV the first signs of acute infection often include lymphadenopathy, 
transient neutropenia, acute diarrhea and mild upper respiratory 
signs (21). This correlates to the general lymphadenopathy and flu­
like symptoms seen in early stages of HIV-1 infection (8). The acute 
phase of each virus is of varying time lengths, and is followed by a 
latent, asymptomatic phase. Virus has been detected during the 
asymptomatic phase, and these cats are classified as asymptomatic 
carriers. An extensive latent period of the FIV is seen in cats (up to 
9 years) as is seen in humans infected with HIV-1 (average 6 years). 
Cats generally show general lymphadenopathy concurrently with 
clinical signs. Humans maintain a general lymphadenopathy while 
appearing otherwise healthy. In cats, it appears that the generalized 
lymphadenopathy stage is either extremely short or occurs at the 
same time that ARC-like symptoms are occurring. The ARC stage in 
cats and humans is characterized by chronic problems including 
lymphadenopathy, stomatitis/gingivitis, skin disease, upper 
respiratory disease, and/or enteric disease (5,21,36,). Neurological 
disorders can accompany either ARC or AIDS stages of both diseases 
(21). Cats progress to full-blown AIDS and die within eight months 
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of the beginning of the ARC stage. Due to the similarity in pathology 
of HIV-1 and FIV in their naturally occurring host, FIV is an obvious 
model for in vivo pathogenesis studies. Additionally, drug-resistant 
isolates can be tested in vivo with FIV. 
Treatment. Due to the important role that RT plays in 
replication of both HIV-1 and FIV, it is an obvious choice as a target 
for antiviral chemotherapy. Currently there are two groups of drugs 
being studied for their inhibiting effect on RT:nucleoside analogs and 
non-nucleoside analogs (fig 3). The non-nucleoside analogs are 
noncompetitive inhibitors of RT and include phosphonoformic acid 
(PFA), nevirapine, tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-
2(1 H)-one (TIBO). In addition, several protease inhibitors are also 
being studied. 
To date, the FDA has only approved nucleoside analogs for 
treatment of humans with AIDS. The four RT inhibitors are the 
nucleoside analogs: 3'-azido-3'-dideoxythymidine (AZT), 2',3'-
dideoxyinosine (ddl), 2',3'-dideoxycytidine (ddC), and 2',3'-dideoxy-
2',3'-didehydrothymidine (d4T). These nucleoside analogs are 
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Figure 3. Nucleoside and pyrophosphate analogs with antiviral 
activities. 
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metabolized by the cell to the corresponding 5'-triphosphate. The 
triphosphates are competitive inhibitors of HIV-1 and FIV RTs. The 
metabolized triphosphates can also be incorporated into the 
elongating DNA strand, causing termination of the chain (10). Since 
both HIV-1 and FIV RT are susceptible to the nucleoside analog 
inhibitors, FIV is an excellent choice as an animal model for drug 
resistance studies. 
Reverse transcriptase biochemical features. Reverse 
transcriptase is the main target for chemotherapy. Not only does 
RT play an essential role in virus replication, it is also unique to the 
virus. FIV and HIV-1 RTs are very similar in physical properties, 
catalytic activity and sensitivity to several RT inhibitors 
(9,29,30,32). The RT of FIV and HIV-1 are extremely similar in both 
template specificity and Mg2+ requirements (30). Our lab has 
purified the RT from FIV and characterized the enzyme with respect 
to its physical and catalytic properties (30). The purified FIV RT 
consists of a p54-p66 heterodimer that is very similar to a p51-p66 
heterodimer that can be generated in HIV-1 RT under proteolytic 
conditions (11,27). Both HIV-1 and FIV RTs used similar amounts of 
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Mg2+ for a given template. Although the RTs of HIV-1 and FIV 
exhibited many similarities with respect to physical properties, it 
has been shown that the two enzymes differ substantially in primary 
sequence (30), as determined by peptide mapping and later confirmed 
by DNA sequence (35,50). When the predicted amino acid sequence of 
FIV RT was compared to that of HIV-1 RT, 60% identity was 
observed (35). The similarity between the two enzymes creates an 
opportunity to study RT inhibitors on a model lentivirus. 
The susceptibilities of FIV RT and HIV-1 RT to various 
inhibitors were also very similar. Inhibition constants for both 
enzymes were determined for several inhibitors, and the two 
enzymes were indistinguishable with respect to the following 
inhibitors: 2',3'-dideoxythymidine 5'-triphosphate (ddTTP), NgdTTP, 
2',3'-dideoxycytidine 5'-triphosphate (ddCTP), 2',3'-dideoxy-2',3'-
didohydrothymidine 5'-triphosphate (d4TTP), 3'-fluoro-3'-
deoxythymidine 5'-triphosphate (3'-F-dTTP), 3'-amino-3'-
deoxythymidine 5'-triphosphate (3'-NH2-dTTP) and two 
noncompetitive inhibitors phosphonoformate (PFA) and 
phosphonoacetate (PAA) (29). Due to the biochemical similarities of 
15 
HIV-1 RT and FIV RT, FIV is also an excellent model for studying 
drug resistance, especially since RT is the target for all approved 
antivirals. 
Drug Resistance. Drug resistance is the limiting factor in the 
treatment of AIDS. AZT was the first drug approved and used for 
treatment (28). Clinically, drug resistance to AZT (25), and 
subsequently ddl and ddC has been reported (13,47). Our lab was the 
first to successfully select an AZT-resistant mutant of a lentivirus 
in vitro (41). This was followed by the selection of AZT-resistant 
mutants of HIV-1 in vitro (16,24). The AZT-resistant mutants of 
FIV have similar phenotypic characteristics to the AZT-resistant 
clinical isolates of HIV-1 (41). Resistance to AZT, ddl and ddC have 
been traced to mutations within the RT-encoding region of the poi 
gene of HIV-1 (19,20,26). The role of these mutations has been 
studied through site-directed mutagenesis and structure/function 
analysis of the RT. 
Since the structure of HIV-1 RT was determined by 
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crystallization, domains and binding sites within RT have been 
identified. The crystal structure of FIV RT has not been determined, 
however, due to the 68% similarity of amino acid sequence of the 
two RTs, it is likely that structures are similar. The polymerase 
domains of p66 and p51 each contain the same four domains, which 
have been called finger, palm, thumb, and connection (23). Most of 
the mutations that confer resistance to nucleoside inhibitors have 
been shown to reside in either the fingers subdomain or the palm 
subdomain. Neither of these locations is in the immediate area of 
the polymerase active site (3). Boyer et al. have proposed that 
resistance to the dideoxynucleotide inhibitors results from a 
repositioning or change in the conformation of the template-primer 
binding to enzyme that alters the ability of the enzyme to select or 
reject an incoming dNTP (3). 
ddC-resistance of HIV-1 has been traced to multiple sites in 
the RT encoding region of the pol gene. These include amino acids 
65, 69, 74, 75, and 184(19,20,48,13). From analysis of the three-
dimensional structure of HIV-1, these sites have been mapped to 
two places. Amino acids 65, 69, 74, and 75 all map within the 
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fingers subdomain of RT and have been implicated in template-
primer interaction (3). Amino acid 184 is near the polymerase 
active site and may work by affecting the positioning of the 
template-primer or by changing residues that directly interact with 
incoming dNTPs. 
ddC-resistant mutants of HIV-1 have arisen through selection 
with ddC, ddl, 3TC and AZT (13,16,19,20,24,47). The phenotypes of 
the ddC-resistant mutants of HIV-1 differ widely. ddC-resistant 
mutants of HIV-1 that were selected by ddC treatment are well 
described (15,16,19,20). One of these mutants was found to be 
cross-resistant to ddl and 3TC. This ddC-resistant mutant of HIV-1 
contained a lesion within the RT-encoding region of the po/gene. In 
addition, Gu et al. have shown that the RT from the HIV-1 ddC-
resistant mutant has reduced sensitivity to ddCTP, 3TCTP, ddATP, 
and AZTTP in vitro (19). This RT exhibited a ten-fold resistance to 
ddCTP compared to wild-type RT. This ten-fold resistance 
corresponds to the ten-fold resistance the virus had to ddC. Gu et al. 
have also selected a ddl-resistant mutant that was cross-resistant 
to ddC (20). Judy Gobert in our lab has selected a ddl-selected 
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mutant of FIV (classified as selected rather than resistant because 
the virus was <5 fold resistant relative to wild-type). In contrast 
to Wainberg's ddl-resistant mutant of HIV-1, the ddl-selected 
mutant of FIV is hyper-sensitive to ddC and also cross-resistant to 
PFA. In order to understand these data further we set out to select a 
ddC-resistant mutant of FIV. 
In order to study drug resistance, it is important to have a 
defined system that is safe and easily manipulated. It is also useful 
to have a system which allows for timely selection of drug-
resistant mutants. FIV has a well-defined cell culture system and 
drug-resistant mutants can be selected readily (43). In addition, 
there is a molecular clone of FIV, FIV 34TF10 with a known sequence 
(50). This molecular clone provides a defined genetic system in 
which to study mutations. Many of the questions raised by drug 
resistance can be best answered in an animal model. Not only can 
drug-resistant mutants be selected and characterized in a cell 
culture system, but the pathogenicity and infectivity of drug-
resistant mutants can be determined in cats (1). Characterization 
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of drug-resistant mutants of FIV offers insight into the mechanism 
of drug-resistance in HIV-1 and can lead to the development of 
better chemotherapeutic agents for AIDS. 
SPECIFIC AIMS 
The goal of this study was to select and characterize a ddC-
resistant mutant of FIV 34TF10. Specific objectives were to select 
variants of FIV that emerge when virus replication occurs in the 
presence of a high concentration of ddC, to determine whether virus 
resistant to ddC are cross-resistant to other antivirals, and to 
determine whether ddC-resistance is due to alterations in reverse 
transcriptase. In addition, the foundation will be laid for studies in 
cats, in which the pathogenicity of ddC-resistant FIV can be 
examined. 
MATERIALS AND METHODS 
Chemicals. The dCTP, Triton X-100, aminoethyl carbazole, 
RFA, -oligo(dC)io-i5, and ddC were purchased from Sigma Chemical 
Co., St. Louis, Mo. AZT was provided by Philip A. Furman of Burroughs 
Wellcome Co., Research Triangle Park, N.C. ddl was provided by the 
Developmental Therapeutics Branch, Division of AIDS, National 
Institute of Allergy and Infectious Diseases. 9-(2-
phosphonylmethoxyethyl)adenine (PMEA) was provided by H.-T. Ho of 
Bristol Myers-Squibb Co., Wallingford, Conn. 2',3'-dideoxy-3'-
thiacytidine (3TC) was provided by Raymond Schinazi of Emory 
University, Atlanta, Georgia. Poly(rA)-oligo(dT)io and Poly(rl) were 
purchased from Pharmacia LKB, Piscataway, New Jersey. 
International Bio Technologies (IBI) phenol for DNA extractions was 
purchased from VWR Scientific. GeneAmp Polymerase Chain 
Reaction (PCR) Core Reagents were purchased from Perkin Elmer 
Cetus, Norwalk, CT. The Taq DyeDeoxy™ Terminator Cycle 
Sequencing Kit was purchased from Applied Biosystems, Foster 
City.CA. All other chemicals were reagent grade or better. 
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Isotopes. [5,-53H]-dCTP and [methyl-3H]dTTP were obtained 
from Dupont-New England Nuclear, Boston, MA. 
Cells and Virus. Virus derived from a molecular clone of the 
Petaluma strain of FIV, 34TF10, was used in this study (50). Wild-
type and mutant strains of FIV were grown and maintained in 
Crandell feline kidney (CrFK) cells. Uninfected and infected cells 
were grown in L & M medium which was composed of equal parts of 
Leibovitz L-15 and Dulbecco's Modified Eagle Medium, supplemented 
with 100 U of penicillin per ml, 100 fjg of streptomycin per ml, 2.0 
mM L-glutamine and 10% fetal bovine serum (FBS). FBS was heat 
inactivated for 30 min. at 56° C. All cultures were maintained at 
37" C in a humidified 5% CO2 atmosphere. ddC-resistant FIV was 
maintained in medium that contained 25 uM ddC, and the medium was 
replaced with fresh medium and the appropriate concentration of 
ddC every 2 days. 
Virus stocks were prepared from medium containing 
extracellular virus released from CrFK cells that had been infected 
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with FiV for more than 21 days. Medium from confluent infected 
cells was centrifuged at 500 X g for 10 min to remove cells. 
Supernatants containing virus, were stored at -80° C in medium 
containing! 0% dimethyl sulfoxide (DMSO). Aliquots of these stocks 
were thawed and used to infect CrFK cells for subsequent studies. 
Focal Infectivity Assay (FIA). The FIA was developed in this 
lab by Remington et al. (41) and is a modification of the FIA 
developed by Chesebro and Wehrly to quantitate HIV-1 (6). In this 
assay, 24-well plates were seeded with uninfected CrFK cells at a 
density of 1.5 x 104 cells per well and incubated for one hour at 37° 
C in growth medium or growth medium containing appropriate 
concentration of drug. This incubation was to allow the cells to 
convert drugs to their active form. These cells were infected with 
FIV and allowed to grow to confluency (4-5 days). The medium was 
replaced with fresh medium and appropriate drug concentration 
every 2 days. When the cells reached confluency, the media was 
aspirated and the cells were fixed with methanol for five minutes. 
The cells were then washed twice with TNE (0.01 M Tris-HCI, pH 7.5 
containing 0.15 M NaCI and 0.002 M EDTA), and once with TNE 
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supplemented with 1% bovine serum. Immunostaining was done by 
incubating the cells for 30 minutes at room temperature with 0.2 ml 
of a 1/200 dilution of polyclonal cat anti-FIV that had been 
obtained from FIV-infected specific-pathogen-free cats. After the 
incubation, cells were washed twice with TNE containing bovine 
serum to remove excess anti-FIV. Next, the cells were incubated for 
40 minutes with 0.2 ml of a 1/600 dilution of horseradish 
peroxidase-conjugated goat anti-cat immunoglobulin (Organon-
Teknika, Durham, NC.). The cells were again washed with TNE and 
then stained with a solution of aminoethyl carbazole in sodium 
acetate buffer, pH 5.0 (1 part per 19 parts buffer). The cells were 
incubated with this substrate for 20 minutes in the dark. After 
incubation, the cells were rinsed three times with water and 
allowed to dry. Infected cells stained red against a clear 
background. A group of four or more infected cells is defined as a 
focus of infection. Foci were examined and counted under 10 to 40 X 
magnification. For visualization, light was reflected off a piece of 
ground glass to reduce the refractivity of the infected cells. For 
dose response curves with drugs, data were plotted as a percentage 
of control plaques (no drug) versus inhibitor concentration. 
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Concentrations required to inliibit focus formation by 50% (IC50 
values) were obtained directly from the linear portion of these 
plots, using a computer-generated regression line. Within an 
experiment, each point represents the mean of four determinations. 
Selection of ddC-resistant mutant. Two 25 cm2 flasks 
containing CrFK cells at 60% confluency were pretreated for one 
hour with 25 ddC to enable conversion of the drug to the active 
form. Cells were infected with 0.9 ml of FIV 34TF10 (approximately 
500 foci of infection per ml). These two cultures were maintained 
by replacing medium and drug every two days and trypsinizing and 
reseeding as necessary. The cultures were monitored weekly for 
virus production by the FIA. When virus was detected in the 
cultures, a second round of infection was initiated using virus from 
the culture with the highest titer, designated DCR-2. Two new 25 
cm2 flasks containing CrFK cells at 60% confluency were pretreated 
for one hour with 25 ji/M ddC. After a one-hour incubation, the cells 
were infected with 0.5 ml of DCR-2 virus containing 400 foci of 
infection per ml. These cultures were maintained as described 
above and monitored weekly for virus production through the FIA. 
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When virus was detected and characterized, plaque-purification of 
the mutant virus was initiated. 
Plaque purification of ddC-resistant mutant. Plaque 
purification of the mutant virus was carried out with a modification 
of the procedure described by Remington et al. (42). Virus was 
plaque purified from the second round of selection, using limiting 
dilutions of virus in the FIA. Limiting dilutions of virus were used 
to infect CrFK cells in 24-well plates in the presence of 25 a;M ddC. 
After six days, each supernatant was transferred to a well of a new 
plate which had been seeded with uninfected CrFK cells in medium 
with 25 /iM ddC. To enhance virus adsorption, just prior to the 
transfer of supernatants, cells of the new plate were treated with 
medium containing 8 ^/g/ml of DEAE dextran for 20 minutes (this 
medium did not contain fetal bovine serum). The original plate was 
stained and examined for those wells that contained a single focus. 
Corresponding wells of the subculture plate were incubated until the 
cells reached confluency. The cells and supernatant from each well 
(corresponding to a well that contained a single focus of infection) 
were transferred to flasks and maintained in medium containing 25 
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IjM ddC. Cultures were monitored weekly for virus production by 
FIA. Only one culture yielded virus, and it was used for further 
characterization, sequence analysis, and RT assays. 
Enzymes. RT was purified from virions of FIV 34TF10 and 
mutant FIV by a method developed by North et al. (30). Briefly, 
virions were disrupted with Triton X-100 and enzyme was purified 
by chromatography on DEAE-cellulose and phosphocellulose. 
Enzyme activity assay. During purification, RT was assayed 
for activity as reported previously (29,30) with poly(rA)-oligo(dT)io 
as the template-primer. Reactions were typically carried out in a 
volume of 50 ij\ and contained 50 mM Tris-HCI, pH 8.5,10 mM 
dithiothreitol, 0.05% Triton X-100, 250 (jg of bovine serum albumin 
(nuclease-free) per ml, 6 mM MgClz, 80 mM KCI, 20 fjM [methyl-
3H]dTTP(33 uCi/ml), 0.5 Azeo units (U) of poly(rA)-oligo(dT)io per 
ml, and appropriate amounts of RT. Samples containing 40 /il were 
taken at 1 hour and spotted onto filters (no. 3, 2.3-cm diameter; 
Whatman, Inc., Clifton, NJ) that had been presoaked with 5% 
trichloroacetic acid-1% sodium pyrophosphate. Filters were dried, 
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washed four times (at least 1 hour each) with 5% tricholoroacetic 
acid-1% sodium pyrophosphate (4° C) and twice with 95% ethanoi, 
dried and then counted in Liquifluor (Dupont-NEN Research Products, 
Boston MA). One unit of RT is defined as the amount of enzyme 
required to catalyze the incorporation of 1 nmol of dTMP per hour 
into poly(rA)-oligo(dT)io at 37" C. 
Enzyme inhibition assay. Inhibition of RT from the ddC-
resistant mutant by ddCTP was compared to inhibition of wild-type 
recombinant FIV RT. Double-reciprocal plots were used to determine 
kinetic constants (Km and Kj) with the template-primer poly(rl)-
oligo(dC)io-i5 and ddCTP as the inhibitor (30). Reactions were 
typically carried out in a volume of 50 ^1 and contained 50mM Tris-
HCI, pH 8.5, 10 mM dithiothritol, 0.05% Triton X-100, 250 /yg of 
bovine serum albumin (nuclease-free) per ml, 6 mM MgClz, 80 mM 
KCI, varying activity of [5,-5'-3H]-dCTP (33, 16.5, 4.9, 3.3, 2.4, and 
1.6 uCi/ml) corresponding to varying concentrations of.dCTP (20, 10, 
6, 4, 3, and 2 pM), 0.5 AzeoU of poly(rl)-oligo(dC)io-i5 per ml, 
varying concentrations of ddCTP (0, 100, 250, and 500 nM), and 
appropriate amounts of RT. Samples containing 40 were taken at 
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1 hour and spotted onto filters (no. 3, 2.3-cm diameter; Whatman, 
Inc., Clifton, NJ) that had been presoaked with 5% trichloroacetic 
acid-1% sodium pyrophosphate. Filters were dried, washed four 
times (at least 1 hour each) with 5% tricholoroacetic acid-1% 
sodium pyrophosphate (4° C) and twice with 95% ethanol, dried and 
then counted in Liquifluor (Dupont-NEN Research Products, Boston 
MA). 
Nucleic acid preparation. Total cellular DNA containing 
pro virus was extracted from CrFK cells that were infected with 
ddC-resistant FIV. Confluent monolayers of infected cells were 
washed three times with TBS (25 mM Tris-HCI, pH 7.4 containing 5 
mM KCI and 137 mM NaCI) and removed from flasks (cells peel from 
flask wall during the last wash). Cells were pelleted at 500 X g for 
10 min. The cells were washed once with TE (lOmM Tris-HCI, pH 7.6 
containing 1 mM EDTA), then resuspended in this buffer. Cell 
suspensions were treated with 0.1 mg/ml Proteinase K and 0.5% SDS 
overnight at 37" C. The cell lysates were then extracted three times 
with phenol that had been equilibrated with 10 mM Tris-HCI, pH 7.5 
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containing 100 mM NaCI and 1 mM EDTA. The aqueous phase was 
collected and dialyzed against four changes of 10 mM Tris-HCI, pH 
7.5 containing 100 mM NaCI and 1 mM EDTA until the A260 of the 
dialysate was less than 0.16. The dialyzed aqueous phase was 
treated with RNase A (0.1 mg/ml) at 37° C for 3 hours. The RNase 
A-treated aqueous phase was extracted with one-half volume 
equilibrated phenol and one-half chloroformrisoamyl alcohol (24:1). 
The aqueous layer was removed and then extracted with an equal 
volume of chloroform:isoamyl alcohol (24:1). The salt concentration 
was adjusted by adding 1 /30 volume of 3 M Sodium acetate, pH 5 to 
the aqueous phase. The DNA was precipitated by adding 3 volumes of 
cold 95% ethanol and incubating overnight at -20° C. The 
precipitated DNA was removed from the ethanol and allowed to dry. 
The DNA was resuspended in sterile water and used for 
amplification using the polymerase chain reaction (PGR). 
PGR amplification and nucleotide sequence analysis. 
Amplification of the RT-encoding region of the pol gene was 
performed using the Perkin-Elmer/Getus GeneAmp PGR protocol. 
Each 100 ^1 reaction contained 10 mM Tris-HGI, pH 8.3, 50 mM KGI, 
200 tjM of each dNTP (dATP, dlTP.dCTP and dGTP), 4 mM MgClz, 0.2 
A/M of each primer, 2.5 Units of AmpliTaq® DNA polymerase, and 10-
20 ^jg of target DNA. Reactions were overlaid with 50-100 ul of 
light mineral oil. The sense primer (5'-GTA ATG TTT GTG TCT TAG 
AAG ATA ACT C-3') and the reverse complement primer (5'-ATC 
ATA TCC TGC ATC TTC TGA CCT-3') were synthesized in the Murdock 
Molecular Biology Facility, University of Montana, Missoula, MT. The 
primers were chosen to amplify a 1763 base pair fragment that 
contained nucleotides 2268 through 4031. The PCR was run for 30 
cycles, each cycle comprised of 30 seconds of denaturation at 94" C, 
30 seconds of annealing at 62° C and two minutes of extension at 
72° C. After PCR, the product was visualized on an agarose gel. For 
this, the mineral oil was separated from the PCR products and an 
aliquot of the mixture was run on a 0.8% low-melting agarose 
electrophoresis gel in 40 mM Tris acetate, pH 7.6 containing 1 mM 
EDTA (45). The agarose gel and running buffer contained 0.5 pg/ml 
ethidium bromide. A 1763 base pair band was identified by 
comparing the electrophoresed PCR reaction to a 1 Kb DNA ladder 
(Gibco BRL, Gaithersburg.MD). The remaining PCR product was 
purified using the QIAquick PCR Purification Kit, Qiagen Inc., 
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Chatsworth, CA. Sequencing was performed In the forward and 
reverse directions with two or more primers covering each 250 base 
pair section of the RT-encoding region along with small flanking 
regions on either end of RT. Four different primers were used to 
sequence the 2342 region containing the point mutation. This DNA 
was directly sequenced by Joan Strange, The Murdock Molecular 
Biology Facility, The University of Montana, Missoula, MT, with a Taq 
DyeDeoxy™ Terminator sequencing kit and analyzed on a Model 373A 
automated DNA sequencer (Applied Blosystems, Foster City, CA). 
RESULTS 
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SELECTION OF ddC-RESISTANT MUTANT 
A ddC-resistant mutant of FIV was selected by infection of 
CrFK cells with FIV 34TF10 in the presence of inhibitory 
concentrations of ddC. For the initial round of selection, two 25 cm2 
flasks of cells were infected with a high multiplicity of infection 
(450 focal forming units/flask). The cells were pretreated with 25 
/iM ddC for one hour prior to infection to ensure that the drug had 
been converted to its active form by the cells. Cells were 
maintained with 25 juM ddC throughout the selection by replacing 
media and drug every two days. The drug concentration (25 ^JM) used 
in this experiment was chosen because it is five times the IC50 
value and should inhibit wild-type virus production completely. 
Cultures were monitored weekly for virus production by the FIA. No 
virus was detectable until 17 weeks post infection. It should be 
noted that virus production in other drug selections (AZT, ddl, PFA 
and FLT) usually takes between 3 and 8 weeks. One of the cultures, 
DCR-2C, was chosen to characterize and to continue selection. Once 
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it was established that the virus was resistant to ddC, a second 
round of selection was initiated (Figure 4). In addition, DCR-2c was 
characterized with respect to other antivirals'(Table 1). Two or 
more dose response curves were performed using ddC and ddl. One 
dose response curve for each of the other antiviral drugs were 
performed for preliminary screening of the ddC-resistant phenotype. 
For the second round of selection, 200 focal forming units of 
undiluted cell-free virus/flask from the first round were used to 
infect two 25 cm2 flasks of CrFK cells that had been pretreated with 
25 A/M ddC. Less virus was used in the second round of selection to 
lower the chance of heterogeneity that might arise from mixed 
infections. The second round cultures were maintained with 25 //M 
ddC and monitored for virus production as before. When virus was 
detected, the second round was characterized (Table 1) and ddC-
resistance was confirmed (Figure 4). The same dose response curve 
protocol as the first round was repeated with this round. Plaque-
purification of the mutant virus was initiated. 
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Figure 4. Inhibition of FIV 34TF10 and DCR-2c (Rounds 1 and 2 of 
selection) by ddC as determined by focal infectivity assay. Results 
are from two experiments and each point represents four 
determinations. Bars represent standard error of the mean, and are 
omitted where the standard error was to small to accurately show 
using error bars. 
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Table 1. Sensitivities of FIV34TF10 and DCR-2c to antiviral 
compounds as determined by FIAa. 
Mean IC50 ( j jM)  ±  SE 
Compound 34TF10 DCR-2c DCR-2c 
Round 1 Round 2 
ddCb 4.9+0.7 30+2 25±1 
ddlb 5.5+0.8 21±1 23±2 
AZT 0.34 0.62 0.50 
PFA 113 >400 >400 
PMEA 0.47 0.37 0.44 
3TC 0.58 0.75 0.65 
a Values represent four determinations per experiment 
b Values are from two or more experiments. 
PLAQUE PURIFICATION OF ddC RESISTANT MUTANT 
In an effort to minimize the degree of heterogeneity within the 
DCR-2C mutant population, the FIA was used to isolate a clone of 
virus that had descended from a single infectious particle. A focus 
of infection represents an infection by a single virion (Fig 5). CrFK 
36 
Figure 5. Focus of FIV-infected CrFK cells detected with polyclonal 
antiserum to FIV and peroxidase-conjugated goat anti-cat 
immunoglobulin. 
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cells were seeded at a density of 1.0 X 104 cells per well in TC24 
plates and were infected with virus stocks that had been diluted to 
contain approximately one infectious particle per well. After six 
days, culture supernatants were transferred to uninfected cells in 
TC24 plates, and the original plates were immunostained to identify 
those wells that contained a single focus of infection. Cells 
infected with progeny from a single infection event were 
transferred along with supernatant to a flask and maintained with 
25 ijM ddC and monitored for virus production by the FIA. Plaque-
purification of the ddC-resistant mutant proved to be difficult. The 
first three times plaque-purification of DCR-2c was attempted, 
virus was lost between the transfer of supernatant to the subculture 
plate and final transfer of supernatants and cells into flasks. 
Multiple wells containing single foci were identified. However, 
corresponding cells and supernatants did not yield infectious virus. 
To enhance virus adsorption to the cells in the subculture plate, the 
plaque-purification protocol developed by Remington et al. was 
modified (41). Before transferring the supernatants from the 
culture plate to the subculture plate, the CrFK cells on the 
subculture plate were treated with serum-free medium containing 8 
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^g/ml of DEAE dextran for 20 minutes. DEAE dextran treatment 
coats the cells with a positive charge, thereby making the cells 
more attractive to the negative charged virus particles. Using this 
modification, supernatants from eighteen isolates were transferred 
onto the DEAE dextran-treated CrFK cells of the subculture plate. 
When the cells and supernatants were transferred to flasks, virus 
was detected in one of the eighteen cultures. This virus, designated 
DCR-Sc, was ddC-resistant (Figure 6) and was characterized against 
a battery of RT inhibitors. 
SUSCEPTIBILITY OF ddC-RESISTANT AND 34TF10 FIV TO ddC 
Susceptibility of virus from each round of selection to ddC 
was assayed with the FIA by determining the number of foci at 
varying concentrations of ddC. The data shown in Figure 5 verify 
that DCR-Zc was considerably less sensitive to inhibition by ddC 
than the molecular clone. The IC50 value for inhibition of DCR-2c by 
ddC was greater than 25 /L/M compared to 5 /JM for FIV34TF10. These 
data confirmed that DCR-2c was at least 5-fold less susceptible to 
ddC than the molecular clone. DCR-5c, the plaque-purified mutant 
derived from DCR-2c, was also less sensitive to inhibition by ddC 
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Figure 6. Inhibition of FiV 34TF10 and DCR-5c by various antivirals 
as determined by focal infectivity assay. Results are from three 
experiments and each point represents four determinations. Bars 
represent standard error of the mean, and are omitted where the 
standard error was to small to accurately show using error bars. 
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than FIV 34TF10. The dose response curve shown In Figure 6 
verified that the IC50 value for inhibition of DCR-5c by ddC was 
greater than 12 compared to 3 for the molecular clone. 
CHARACTERIZATION OF ddC-RESISTANT MUTANT 
Susceptibility to antiviral compounds. The susceptibility of 
virus from each round of selection to a variety of other antiviral 
compounds was determined using the FIA and compared to the 
susceptibilities of wild-type virus (Table 1). These data showed 
that DCR-Zc is cross-resistant to ddl and PFA. DCR-2c is also 
slightly less sensitive to 3TC than wild-type FIV 34TF10. The 
mutant FIV was similar to FIV 34TF10 in sensitivity to AZT and 
PMEA. Of the compounds tested, the mutant exhibited resistance to 
a similar dideoxynucleoside analog (ddl), and, interestingly, to a 
non-nucleoside analog (PFA). The IC50 value for inhibition of DCR-2c 
by ddl was greater than 13 ^/M compared to 3 jwM for FIV34TF10. 
DCR-Zc demonstrated an IC50 value for PFA of greater than 400 uM 
compared to 75 pM for FIV 34TF10. The IC50 values obtained for 
inhibition of FIV 34TF10 and ddC-resistant FIV are summarized in 
Table 1. 
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The drug susceptibility of DCR-5c was determined to confirm 
that the phenotype of the mutant had not changed during plaque-
purification. The sensitivities to ddC, ddl, AZT, PFA, PMEA, and 3TC 
of this plaque-purified mutant were compared to the molecular 
clone (Figure 6 and Table 2). Referring back to Table 1, it can be 
seen that the phenotype of the plaque-purified mutant (DCR-5c) 
remained similar to the mutant population (DCR-2c). The plaque-
purified mutant demonstrated resistance to ddC, ddl and PFA, slight 
resistance to 3TC, and wild-type sensitivities to all other drugs 
tested. 
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Table 2. Sensitivities of FIV 34TF10 and DCR-5c to antiviral 
compounds, as determined by FIAa. 
Mean IC5oG/M)+SE 
Compound FIV3 4TF10 DCR- 5C  
ddC 3.5+0.6 13±0.6 
ddl 3.0+0.4 9.8+0.5 
AZT 0.3+0.2 0.5+0.1 
PFA 78±9.0 >600 
PMEA 0.3+0.1 0.5+0.1 
3TC 0.5+0.1 0.8±0.1 
a Values are from three experiments, with four determinations per 
experiment. 
Reverse transcriptase. Reverse transcriptase was purified from 
DCR-Sc and the kinetic parameters of inhibition by ddCTP were 
determined and compared to the wild-type FIV RT (R-RT). As 
expected, ddCTP displayed competitive inhibition of the enzymes 
(Figure 7). The wild-type FIV RT was produced in Escherichia coli, 
and has been shown to be similar to virion-derived FIV RT in 
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Figure 7. Determination of Kj values for inhibition of wild-type 
recombinant RT and DCR-5c RT. Values reported are averages from 
duplicate determinations. 
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susceptibility to ddCTP and other antiviral nucleotides (31). The 
two enzymes had comparable Km values for both dTTP and dCTP. 
However, the mutant enzyme was ten times less sensitive to ddCTP 
compared to the recombinant RT. Wild-type FIV RT had an IC50 value 
of 49 nM compared to the mutant RT IC50 value of 456 nM (Figure 7, 
Table 3). Future experiments should determine whether the mutant 
RT is susceptibility to ddATP (the active form of ddl), PFA, and 
AZTTP. 
Table 3. Comparison of kinetic constants for RT from FIV 34TF10 
and DCR-5ca. 
FIV Km for dCTP Kj for ddCTP K/Km 
(juM) (nM) 
34TF10 6.2±1.3 49±2.3 .008 
DCR-5C 11±1.2 456±27 .04 
a Values are means + standard error from 2 or more determinations. 
Nucleotide sequence analysis. Sequence analyses of the RT-encoding 
region of the pol gene from DCR-5c and FIV 34TF10 were performed 
in the forward and reverse directions. The results are shown in Fig. 
8. FIV 34TF10 DNA had been subcloned into the 
lyAanVaiCy sVaiLauGiu AsoAsnSerL euIleGlaPr oLatiLauCly ArgAsoAsnM etIleLysPh 
GTAATCrrrG TCTCTTACAA GATAACTCAT TAATACAACC ATTATTGGGG AGAGATAATA TGATTAAATT 2310 
piasmid 
FIV34TriO 
OCR-5c 
>rt: 5 10 15 
eAsnlleArg LeuValMecA laGlnXleSe rAaoLvsIle ProVaiValL ysValLvsMe tLysAsoPro 
CAATATTACG TTAGTAATGC CTCAAATTTC TGATAÀGATT CCAGTACTAA AACTAAAAAT GAAGGATCCT 2380 
—— — — — piasmid 
FIV34TF10 
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His 
20 25 30 35 
AsnLysGIyP roGInlleLy sGlaTrpPro LeuThrAsnG LuLysIleGl uAiaLauThr GluIleVaiG 
AATAAAGGAC CTCAAATAAA ACAATGGCCA TTAACAAATG AAAAAATTGA AGCCTTAACA GAAATAGTAG 2450 
—  — _______ — « —  -— —  oiasiaid 
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TATAAAAAAG AAAAGTGGAA AATGGAGAAT GCTCATAGAT TTTAGAGAAT TAAACAAATT AACTGAGAAA 2590 
piasmid 
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GlyAiaGluV alGlxsLeuGl yLeuProffis ProAlaGlvL euGInXIeLy sLysGlnVai ThrValLeuA 
GGAGCAGACG TCCAGTTGGG ACTACCTCAT CCTGCTGGTC TACAAATAAA AAAACAAGTA ACAGTATTAG 2660 
piasmid 
fIV34TF10 
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spIIeGlyAs pAlaTyrPhe ThrlleProL euAsoProAs pTyrAlaPro TyrThrAiaP heThrLeuPr 
ATATAGCGGA TGCATATTTC ACCATTCCTC TTGATCCAGA TTATGCTCCT TATACAGCAT TTACTTTACC 2730 
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oArgLysAsn AsnAlaGlvP roGiyArgAr gPhaValTrp CysSarLauP roGlnGlyTr pflaLauSar 
TAGCAAAAAT AATGCGGGÂC CAGGAAGGAC ATTTGTCTGC TGTAGTCTAC CACAAGGCTG GATTTTAAGT 2800 
piasmid 
FIV34TF10 
DCa-5c 
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ProLauIlaT yrClaSarTh rLatiAspAsa IlalleGlaP roPtiallaAr çGInAsnPro GlaLauAspX 
CCATTGATAT ATCAAACTAC ATTAGATAAT ATAATACAAC CTTTIATTAG ACAAAATCCT CAATTAGATA 2870 
piasmid — frV34TF10 
— oca-5c 
Figure 8. (cont on next page) 
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Figure 8. Nucleotide sequence and deduced amino acid sequence of 
RT-encoding region of pol gene from 34TF10 clone of FIV in pUCI 19, 
virus derived from this molecular clone, and DCR-5c. denotes 
Identity. 
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plasmid pUCI 19 and was used as a sequencing wild-type control. 
The sequence of DCR-5c was identical to the 34TF10 clone of FIV in 
pUC119 and virus derived from this molecular clone except for a 
single point mutation at position 2342 of a G to a C. This resulted in 
the replacement of aspartate with histidine at the third amino acid 
of RT, which produced a negative to positive change in the amino 
acid charge. 
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DISCUSSION 
We report the first successful selection of a ddC-reslstant 
mutant of FIV. This was the first ddC-resistant mutant from a 
molecular clone of either FIV or HIV-1. This mutant was selected by 
the method developed by Remington et al. (41) using a drug 
concentration that is known to completely inhibit replication of 
wild-type FIV in vitro. This ddC-resistant mutant of FIV proved to 
be unique in several ways. First, DCR-2c was not detectable in cell 
culture until 17 weeks post-infection. This is at least twice the 
length of time it takes for selection of mutants to AZT, ddl, PFA or 
3 '-fluoro-3 '-deoxythymidine (FLT) (3-8 weeks). Although no direct 
correlations to the clinical setting can be drawn, at least within our 
well-defined cell culture system, It appears that ddC resistance 
arises more slowly than to other RT inhibitors. 
The second unique quality of DCR-2c was the difficulty it 
posed in plaque-purification. Using the established plaque-
purification protocol developed by our lab, I was unable to obtain 
virus production in four attempts starting with 30 possible single 
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foci. Even with the modified version, only one culture produced 
virus out of eighteen possible single foci. DCR-2c is the only drug-
resistant mutant selected by our lab that was difficult to plaque-
purify. The reason for this difficulty in plaque-purification is not 
known. 
Thirdly, it is interesting that both DCR-2c and DCR-5c 
exhibited unusually high titers when virus was finally produced. The 
high titer displayed by the ddC-resistant mutants was in stark 
contrast to the other drug resistant mutants selected by our lab, 
most of which yielded titers 5 to! 0-fold lower. 
The plaque-purified ddC-resistant mutant of FIV, DCR-5c, 
demonstrated similar phenotypes when compared to the mutant 
population, OCR-2c. In addition, DCR-5c showed some similarities 
to the ddC-resistant mutant of HIV-1 selected by Gu et al. (20). 
Both DCR-Sc and the HIV-1 mutant demonstrated cross-resistance 
to ddl and wild-type susceptibility to AZT (20). However, DCR-5c 
exhibited only a slight resistance to 3TC, whereas Gu et al. reported 
a 500-fold resistance of the HIV-1 mutant to 3TC (20). These 
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differences may be due to the different selection methods used to 
select HIV-1 drug resistant mutants. The HIV-1 mutants were 
selected by gradually increasing drug concentrations in a step-wise 
method during the selection process. This protocol has been used 
because researchers have had difficulty selecting mutants of HIV-1 
with high drug concentrations, as used in FIV selections. Gu et al. 
did not test inhibition by PMEA or PFA, so we cannot compare these 
phenotypes. In addition to the similarities in the two mutants 
susceptibility to ddC and ddl, the RTs of the two mutants were also 
similar in that they were resistant to ddCTP. 
Reverse transcriptases were purified from wild-type and the 
plaque-purified ddC-resistant mutant (DCR-5c) of FIV. The RT from 
the mutant virus was resistant to the active form of ddC, ddCTP, 
compared with wild-type RT. DCR-5c showed a ten-fold increase of 
resistance. This compares to the 20-fold Increase of resistance 
shown by the ddC-resistant mutant of HIV-1 that Gu et al. described 
(19.). Assays of both RTs used poly(rl)-oligo(dC) as template-primer 
and dCTP as substrate. Although the RT appears to show a higher 
resistance to ddCTP than the virus replication did to ddC, the ratio 
Kj/Km used to normalize for changes in substrate recognition by the 
enzyme was increased approximately 5-fold with the mutant virus. 
These findings are consistent with the 5-fold increase in IC50 for 
inhibition of replication of OCR-5c by ddC. It appears that the 
mutation in the RT-encoding region confers resistance to ddC. 
Although it may seem intuitive that the RT of a drug-resistant 
mutant would be resistant to the ddNTP, this has not always been 
the case. Many studies have described isolation or selection of drug 
resistance FIV and HIV-1 that had RTs susceptible to the ddNTPs 
(26,41,55). 
The resistance shown by the RT from DCR-5c can be correlated 
to sequence analysis. The ddC-resistant mutant that was derived 
from the 34TF10 clone of FIV enabled examination of the nucleotide 
sequence of ddC-resistant FIV. Sequence analysis of the RT-
encoding region of the pol gene revealed a single base change in the 
mutant FIV, as compared to the FIV34TF10 wild-type. The 
nucleotide substitution at position 2342 in DCR-5c was the only 
divergence from the wild-type RT-encoding region. This 
substitution produced an asp-3 to a his amino acid change, resulting 
53 
in a negative to positive charge alteration. This is a significant 
change that would possibly result in a conformational modification 
of the RT. Asp-3 resides in an area analogous to where the 
template-primer binds during DNA elongation within the HIV-1 RT 
(23). This is based on HIV-1 structure and assumptions of 
similarities. Because of the RT data, it is likely that this mutation 
within RT is responsible for the ddC-resistance. No drug-resistance 
mutation has previously been mapped to this area in either FIV or 
HIV-1. This mutation in DCR-5c provides information regarding 
possible new sites for drug resistance. 
Some of the mutations responsible for ddC-resistance of HIV-
1 are also located within the finger-like domain of RT (15,16,19,20). 
Although the codon 3 of the ddC-resistant mutant is located close to 
the amino terminus end, it also is located within the finger-like 
domain, and therefore is in position to interact with the template-
primer. Boyer et al. proposed that resistance to the 
dideoxynucleotide inhibitors results from a repositioning or change 
in the conformation of the template-primer that alters the ability of 
the enzyme to select or reject an incoming dNTP (3). 
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Conduisions and future directions. We have successfully 
selected a ddC-reslstant mutant of FIV by culture of FIV in the 
presence of a high concentration of ddC (41). In order to further 
characterize ddC-resistant mutants with respect to the HIV-1 
mutants, it would be useful to perform a step-wise ddC selection 
with FIV, under conditions similar to those used by Gao et al (16). 
Comparison of selection methods would answer whether selection 
methods play a role in the phenotype and genotype of drug resistant 
mutants. In addition, it would be extremely interesting to determine 
the susceptibility of RT from DCR-5c to ddATP, the active form of 
ddl, AZTTP, and PFA. The results from these experiments could 
confirm that the RT does in fact confer the phenotype of the whole 
virus. 
Reversion and/or site-directed mutagenesis studies would provide 
additional confirmation whether the single point mutation is 
responsible for resistance of the RT to ddCTP and the virus to ddC. 
Reversion studies would also provide information on the stability of 
the drug-resistant population. 
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Lastly, in vivo studies would be especially useful for pathogenicity 
studies. Due to the similarities between FIV and HIV-1, in vivo 
studies would provide information on whether ddC-resistant 
mutants are pathogenic. 
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